Daewoong Pharmaceutical Co., Ltd.

Global Botulinum Toxin Market Poised to Reach $29 Billion by 2035, Driven by Aesthetic Democratization and Expanding Therapeutic Indications

- The global botulinum toxin market is projected to grow from an estimated $9.59 billion in 2026 to $29.08 billion by 2035, registering a CAGR of 13%. - North America holds the largest revenue share at approximately 42.5%, while Asia-Pacific is expanding at the fastest CAGR of roughly 11.4%. - Key industry players including AbbVie (Allergan), Galderma, Merz Pharma, and Daewoong are advancing liquid-stable formulations, purified neurotoxins, and expanded manufacturing capacity. - Therapeutic applications beyond aesthetics—including chronic migraine, spasticity, and cervical dystonia—continue to broaden the clinical utility and commercial reach of botulinum toxin products.